Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Unusually-High Trading Volume – What’s Next?

Posted by Grant Hamersma on Jul 17th, 2026

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) saw an uptick in trading volume on Friday . Approximately 351,670 shares traded hands during trading, an increase of 151% from the previous session’s volume of 140,259 shares.The stock last traded at $12.0870 and had previously closed at $12.07.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday, June 23rd. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy”.

Read Our Latest Report on Fresenius SE & Co.

Fresenius SE & Co. Trading Up 0.4%

The stock has a 50-day simple moving average of $11.42 and a 200 day simple moving average of $12.94. The company has a current ratio of 1.27, a quick ratio of 0.98 and a debt-to-equity ratio of 0.41. The company has a market cap of $27.31 billion, a price-to-earnings ratio of 16.16 and a beta of 0.63.

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Fresenius SE & Co. had a net margin of 6.55% and a return on equity of 10.09%. The firm had revenue of $6.75 billion during the quarter, compared to analyst estimates of $6.79 billion. As a group, equities research analysts predict that Fresenius SE & Co. will post 1.03 EPS for the current fiscal year.

Fresenius SE & Co. Company Profile

(Get Free Report)

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.